AISF position paper on liver disease and pregnancy  by Morisco, Filomena et al.
SA
T
a
A
R
A
A
K
L
P
1
s
p
o
a
c
w
o
d
d
F
V
A
G
C
K
V
o
t
N
h
1Digestive and Liver Disease 48 (2016) 120–137
Contents lists available at ScienceDirect
Digestive  and  Liver  Disease
journa l h om epage: www.elsev ier .com/ locate /d ld
pecial  Article
ISF  position  paper  on  liver  disease  and  pregnancy
he  Italian  Association  for  the  Study  of  the  Liver  (AISF)
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 15 June 2015
ccepted 6 November 2015
vailable online 14 November 2015
eywords:
iver diseases
regnancy
a  b  s  t  r  a  c  t
The  relationship  between  liver  disease  and  pregnancy  is  of great  clinical  impact.  Severe  liver  disease  in
pregnancy  is  rare; however,  pregnancy-related  liver  disease  is  the  most  frequent  cause  of  liver  dysfunc-
tion  during  pregnancy  and represents  a severe  threat  to foetal  and  maternal  survival.  A rapid  differential
diagnosis  between  liver  disease  related  or unrelated  to pregnancy  is  required  in women  who  present
with  liver  dysfunction  during  pregnancy.  This  report  summarizes  the  recommendation  of  an  expert  panel
established  by the  Italian  Association  for the  Study  of  the  Liver  (AISF)  on  the  management  of liver  disease
during  pregnancy.  The  article  provides  an overview  of  liver  disease  occurring  in  pregnancy,  an  update  on
the key  mechanisms  involved  in  its pathogenesis,  and  an  assessment  of the  available  treatment  options.The report  contains  in three  sections:  (1) speciﬁc  liver  diseases  of  pregnancy;  (2)  liver  disease  occurring
during  pregnancy;  and (3) pregnancy  in  patients  with  pre-existing  chronic  liver  disease.  Each  topic  is
discussed  considering  the  most  relevant  data  available  in  literature;  the  ﬁnal  statements  are  formulated
according  to both  scientiﬁc  evidence  and  clinical  expertise  of  the involved  physicians,  and  the  AISF expert
panel  recommendations  are  reported.
 Gast© 2015  Editrice
. Introduction
The relationship between liver disease and pregnancy is a poorly
tudied topic and speciﬁc suggestions for the management of these
atients are lacking.
The present document was generated by the Gender Committee
f the Italian Association for the Study of the Liver (AISF) to provide
n ofﬁcial position paper in a setting characterized by uncertain
linical behaviour and lack of uniform approach.
For this reason, two Expert Opinion Meetings were organized
ith the aim of ﬁne-tuning recommendations for the management
f liver disease in pregnancy. The two meetings were held in Rome
uring the AISF Annual Meeting in February 2014 and in Naples
uring the AISF Monothematic Conference in October 2014.
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Primary objective of this document is to provide recommen-
dations for clinical practice deﬁning the best management of liver
disease in relation with pregnancy. The format of recommendations
was chosen to offer a documented approach to pregnant patients
with liver disease.
The report is structured in three parts:
1. Speciﬁc liver disease of pregnancy.
2. Occurrence of liver disease during pregnancy.
3. Pregnancy in patients with chronic liver disease.
The issues related to liver transplantation and pregnancy were
not considered in this report due to space constraints. A publication
by the AISF expert panel on this topic will be forthcoming.
The recommendations were drawn using the level of evidence
and strength of recommendations graded according to the Amer-
ican College of Cardiology and the American Heart Association
Practice Guidelines, listed in Supplementary Table S1.
2. Speciﬁc liver diseases of pregnancy
2.1. Physiological changes in liver during pregnancyIn pregnancy, the liver is affected primarily by circulatory and
hormonal changes. Pregnancy is associated with a hyperdynamic
circulatory status in which cardiac output increases. Blood ﬂow
to the liver remains unchanged, but the percentage of cardiac
 rights reserved.
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utput to the liver is reduced, which may  impair clearance of
ubstances requiring extensive hepatic metabolism [1]. The physi-
logical changes of normal pregnancy mimic  abnormalities that are
ssociated with liver disease in non-pregnant individuals (Supple-
entary Table S2). Because of the hyperestrogenic state, up to 60%
f pregnant women may  exhibit spider naevi or palmar erythema.
all bladder motility is also decreased [2].
.2. Hyperemesis gravidarum
Hyperemesis gravidarum (HG) occurs in 0.1–2.0% of all preg-
ancies and presents with ptyalism, spitting, nausea and vomiting
eading to dehydration, ketosis and weight loss of 5% or more. It can
tart as early as week 4 and typically resolves by week 18 [3,4].
Risk factors include increased body mass index (BMI), psy-
hiatric illness, molar pregnancy, pre-existing diabetes, multiple
regnancies and HG in a previous pregnancy. Hyperthyroidism is
bserved in about 60% of cases likely because of increased thyroid-
timulating activity by human chorionic gonadotropin (HCG).
The pathophysiology appears to have a complex metabolic back-
round [5]. Hormones such as HCG, prolactin and oestradiol have
een implicated [6].
Persistent vomiting may  lead to postural hypotension, tachycar-
ia, electrolyte disturbances, ketosis, muscle wasting and weight
oss [7,8]. Jaundice is uncommon, but indicates liver involvement
hen present. No single conﬁrmatory test exists, however clin-
cal symptoms and biochemical abnormalities, including raised
erum urea and creatinine, hypophosphataemia, hypomagnesiu-
ia  and hypokalaemia, are suggestive for HG [9]. Abnormal liver
unction tests are found in about 50% of patients with HG [4]: mild
minotransferase elevation (up to 200 U/l) is the most common
iver laboratory abnormality, while elevation greater than 1600 U/l
as been reported rarely; alkaline phosphatase may  rise to twice
ormal values; both indirect and direct hyperbilirubinemia up to
 mg/dL may  also occur; serum amylase and lipase may  rise up to 5
imes normal values. Interestingly, the severity of nausea and vomi-
ing in patients with liver involvement correlates with the degree
f liver enzyme elevation [5].
Treatment is supportive and includes intravenous rehydration,
ntiemetics, gradual reintroduction of oral intake and vitamins
upplementation (vitamin B1 or thiamine, vitamin B6, vitamin B12,
itamin C). Early administration of high-dose thiamine (150 mg
aily orally or 100 mg  weekly intravenously) to prevent Wer-
icke’s encephalopathy is suggested [7,8]. Among anti-emetics,
opamine agonists (metoclopramide 5–10 mg  every 6 hours
nd domperidone 10–20 mg  every 6–8 hours), phenothiazines
prochlorperazine 5–10 mg  every 8 hours) and antihistamines
promethazine 12.5–25 mg  every 4–6 hours) have all been shown
o be safe. H2 receptor antagonists have been used occasionally
ith some beneﬁt [9].
The use of the 5-hydroxytryptamine (5-HT3) receptor blocker
ndansetron (8 mg  every 12 hours) has been reported to be safe in
ntractable hyperemesis.
Most patients usually need 5–8 days of hospital admission with
 self-limiting disease but relapse is common. Serious morbidity
an result only from inadequate or inappropriate treatment. As HG
esolves by 18 weeks, lactation is not contraindicated.
ISF expert panel recommendations:
Intravenous rehydration (Class I, Level C), anti-emetics (meto-
clopramide 5–10 mg  every 6 hours, or domperidone 10–20 mg
every 6–8 hours, or prochlorperazine 5–10 mg  every 8 hours,
or promethazine 12.5–25 mg  every 4–6 hours), gradual rein-
troduction of oral intake and vitamins (Class I, Level A) are
ﬁrst line treatments of HG. Disease 48 (2016) 120–137 121
• High-dose thiamine (150 mg daily orally or 100 mg  weekly
intravenously) should be given to prevent Wernicke’s
encephalopathy in women with HG (Class I, Level A).
2.3. Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) usually occurs dur-
ing the last trimester and has a rapid post-natal resolution [10].
It is characterized by severe pruritus, associated with increase in
serum bile acid and aminotransferases. The symptoms and bio-
chemical abnormalities resolve rapidly after delivery but may  recur
in subsequent pregnancies and with the use of hormonal contra-
ception [11]. Interestingly, serum autotaxin, a lysophospholipase
D essential for angiogenesis and neuronal development during
embryogenesis, was found to be a highly sensitive, speciﬁc and
robust diagnostic marker distinguishing ICP from other pruritic
disorders of pregnancy and pregnancy-related liver disease [12].
The incidence of ICP ranges between 0.5% and 1.8% of pregnan-
cies in Europe, but the highest peak of incidence has been reported
in Chile (up to 28% in the Araucanic population) and in Scandi-
navia [13]. Genetic defects in at least 4 canalicular transporters
can be found in ICP (Supplementary Table S3). Genetic variations
may  implicate heterozygous or homozygous mutations located in
different positions of the genes. All the association studies with
these candidate genes stress the complex variability of genotypes,
the different penetrance, and the inﬂuence of several environmen-
tal factors. A recent study utilizing micro-array technology in 12
women with ICP and in 12 healthy controls, found that twenty
genes were potentially correlated to ICP [14]. Among these, an up-
regulation of GABRA2 receptor gene (that codes for a subunit of the
gamma-aminobutyric acid type A receptor) may  indicate that GABA
may  play a role in the pathogenesis of pruritus in this condition.
Severe ICP (with serum bile acids >40 mol/L) is associated with
adverse pregnancy outcome [15].
The current medical treatment for ICP is ursodeoxycholic acid
(UDCA), which acts as several mechanisms of action: protection
of hepatocytes and cholangiocytes by replacing endogenous, cyto-
toxic bile salts, induction of expression of functional transporters at
transcriptional and post-transcriptional level, and enhancing bile
ﬂow [16]. A recent meta-analysis including 9 published random-
ized controlled trials (3 double blind) that compared the effect of
UDCA to other drugs, placebo, or no speciﬁc treatment in patients
with ICP, demonstrated that UDCA is effective in reducing pruritus
and improving liver tests in patients with ICP [17].
AISF expert panel recommendations:
• Management of ICP should be performed by a dedicated team;
monitoring of serum bile acids is recommended, although
there is no general consensus on a correlation between severe
complications and high serum bile acid levels (Class III, Level
A).
• Ursodeoxycholic acid at a dosage of 15 mg/kg of body weight
is safe and effective in the management of symptoms of ICP
(Class IIa, Level A).
2.4. Eclampsia and preeclampsia
Pre-eclampsia occurs after 20 weeks of pregnancy and/or within
24–48 hours after delivery. It affects 5–10% of all pregnancies and
can involve the kidney, the liver, the central nervous and haema-
tological system. Pre-eclampsia is characterized by hypertension
and proteinuria (greater than 300 mg  in 24 h). Presence of seizures
differentiates eclampsia from pre-eclampsia [18].
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Risk factors include extreme maternal age (<16 years and >45
ears), primiparity, pre-existing hypertension, family history and
ccurrence in a previous pregnancy [18].
The pathophysiology involves suboptimal utero-placental per-
usion associated with systemic inﬂammatory response and
ascular endothelial dysfunction. Genetic predisposition and
mbalance of prostacyclin and thromboxane have also been impli-
ated [19].
Clinical features include right upper quadrant pain, headache,
ausea and vomiting. Abnormal liver tests, secondary to vasocon-
triction of the hepatic vascular bed, occur in 20–30% of patients
nd include 10-to-20-fold elevation in aminotransferases, eleva-
ions in alkaline phosphatase and bilirubin increase of less than
 mg/dL [20].
Pre-eclampsia and eclampsia are associated with 3-to-25-fold
ncreased risk of pulmonary oedema, abruption, aspiration pneu-
onia, renal failure, hepatic failure, disseminated intravascular
oagulation (DIC), and stroke. Haemorrhagic stroke is the most
ommon cause of death, vascular disease, renal, and neurological
equelae. Most cases resolves within 12 weeks postpartum [21,22].
Maternal mortality is 15–20% while foetal mortality is 1–2% of
ive births [23,24].
Close monitoring of blood pressure and proteinuria is neces-
ary during pregnancy. First line of hypertension treatment in
regnant women with pre-eclampsia is labetolol, methyldopa or
ifedipine. Treatment is aimed to keep the systolic blood pressure
elow 150 mmHg  and the diastolic between 80 and 100 mmHg.
agnesium sulphate remains the drug of choice for seizure pro-
hylaxis in severe preeclampsia and for controlling seizures in
clampsia. Treatment consists in early delivery whenever possible
23,24]. Breast-feeding is not contraindicated in women  on anti-
ypertensive therapy post-partum: nifedipine, labetalol, atenolol,
ethyldopa, captopril and enalapril have been shown to be safe
25]. Magnesium sulphate is excreted in breast milk but is safe for
reastfed infants.
ISF expert panel recommendations:
Labetolol, methyldopa or nifedipine are ﬁrst-line treatments
for pre-eclampsia (Class I, Level A).
Magnesium sulphate should be given for seizure prophy-
laxis in severe pre-eclampsia and for controlling seizures in
eclampsia (Class I, Level A).
In pre-eclampsia, early delivery should be performed when
gestational age is over 37 weeks or maternal-foetal conditions
are deteriorating (Class I, Level A).
Breast-feeding is not contraindicated in pre-eclamptic women
on antihypertensive therapy: nifedipine, labetalol, atenolol,
methyldopa, captopril, and enalapril can be used safely (Class
III, Level B).
.5. HELLP syndrome
The haemolysis, elevated liver enzymes, and low platelets
HELLP) syndrome is associated with endothelial cell injury and
icroangiopathic platelet activation and consumption. It occurs in
–20% of pre-eclampsia [25].
The disorder can be diagnosed antepartum (in 70% of cases
etween 27 and 30 weeks) or postpartum. Risk factors are advanced
aternal age, multiparity and Caucasian ethnicity.
The pathophysiology remains unknown: activation endothe-ial cells may  lead to release of Von Willebrand factor multimers
hich are highly reactive with platelets. The syndrome seems to be
he ﬁnal manifestation of some insult that leads to microvascular
ndothelial damage and intravascular platelet activation [26,27]. Disease 48 (2016) 120–137
Patients may  present with right upper quadrant and epigastric
pain, nausea, vomiting, and malaise. Hypertension and protein-
uria are evident in up to 85% of cases. Because of the haemolysis,
high serum unconjugated bilirubin and lactate dehydrogenase are
frequent [28,29], as well as a moderate rise in liver enzymes. In
later stages, DIC may  be present with increased levels of ﬁbrin
degradation products and d-dimer, and thrombin–antithrombin
complexes. Two  recognized classiﬁcations of HELLP (known as the
Tennessee and the Mississippi systems) are available [30].
Complications include DIC, pulmonary oedema and placental
abruption. Perinatal mortality rate is 6–70%, while maternal mor-
tality is 1% [31].
Once HELLP develops, the only deﬁnitive treatment is delivery
of foetus. If the gestational age is between 24 and 34 weeks, cortico-
steroids are usually given to promote foetal lung maturity. Delivery
should be considered 24 hours after administration. After delivery,
close monitoring of the mother should continue, as some women
may  have worsening thrombocytopenia and increasing LDH levels
up to 48 hours postpartum [27,31]. As in pre-eclampsia, breast-
feeding is not contraindicated in HELLP syndrome and for women
receiving antihypertensive therapy; nifedipine, labetalol, atenolol,
methyldopa, captopril and enalapril have been shown to be safe
[32].
AISF expert panel recommendations:
• Delivery of the foetus is ﬁrst-line treatment of HELLP syn-
drome before 24 or after 32 weeks gestation and in presence
of maternal-foetal complications (Class I, Level B).
• In HELLP syndrome between 24 and 34 weeks’ gestation, cor-
ticosteroids should be given to promote foetal lung maturity
(Class I, Level A) and delivery should be considered 24 hours
after corticosteroids administration (Class I, Level A).
• Breast-feeding is not contraindicated in women with HELLP
syndrome on antihypertensive therapy: nifedipine, labetalol,
atenolol, methyldopa, captopril, and enalapril can be used
safely (Class III, Level B).
2.6. Acute fatty liver of pregnancy
Acute fatty liver of pregnancy (AFLP) is a microvescicular fatty
inﬁltration of hepatocytes and a common cause of liver failure in
pregnancy. It is a late-gestational complication, often occurring at
week 28–40. It is a rare disorder affecting from 1:7000 to 1:16,000
pregnancies, but it is a medical and obstetrics emergency [33]. Risk
factors are nulliparity, preeclampsia, multiple gestation, pregnan-
cies with a male foetus, low BMI  [33].
The aetiology is unknown. Defects in intra-mitochondrial fatty
acid beta-oxidation (enzymatic mutations), in particular a homozy-
gous foetal deﬁciency of the enzyme long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD) in a mother carrying a heterozygous
LCHAD deﬁciency can be found [34]. Hepatotoxic metabolites pro-
duced by the foetus and/or placenta may  cause liver disease in the
heterozygous mother when combined with the metabolic stress of
the third trimester [34,35]. However, AFLP may  occur in the absence
of known genetic mutations [36].
The initial manifestations of AFLP include headache, fatigue,
nausea and vomiting. Clinical presentation may  vary from abdom-
inal pain, jaundice, signs of preeclampsia (50%), hypoglycemia,
hepatic encephalopathy, coagulopathy (DIC). Biochemical ﬁndings
include elevated aminotransferases levels (from mild elevation
to 1000 IU/L, usually 300–500), elevated bilirubin (frequently
>5 mg/dL), leukocytosis, anaemia, thrombocytopenia and hypoal-
buminemia, increased uric acid, renal impairment, metabolic
acidosis, hyperammonemia, biochemical pancreatitis. Differential
diagnosis is with HELLP syndrome (Table 1) [37,13]. The diagnosis
Special Article / Digestive and Liver
Table  1
Differential diagnosis between haemolysis, elevated liver enzymes, and low
platelets syndrome and acute fatty liver of pregnancy.
HELLP AFLP
Prevalence (%) 0.2–0.6 0.005–0.01
Onset Third trimester or
post-partum
Third trimester or
post-partum
Family history No Occasionally
Onset of preeclampsia (%) 70–80 50
Clinical features Haemolysis
(anaemia)
Thrombocytopenia
(50,000 platelets)
Liver failure,
coagulopathy,
encephalopathy
hypoglycemia, DIC
Aminotransferases Mild increase (may
be up to 10–20 fold)
300–500 UI/L typically
Bilirubin <5 mg/dL unless
massive necrosis
>5 mg/dL
Liver imaging Hepatic infarcts,
hematomas, rupture
Fatty inﬁltration
Histology Patchy/extensive,
necrosis, periportal
haemorrhage, ﬁbrin
deposits
Microvescicular
steatosis in zone 3
Maternal mortality (%) 1–25 7–18
Foetal/perinatal mortality
(%)
11 9–23
Recurrence in subsequent
pregnancy (%)
4–19 25 (fatty acid oxidation
defects)
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s based on clinical and laboratory ﬁndings. Liver biopsy is the gold
tandard although rarely necessary [38].
Complications include encephalopathy, thrombocytopenia, DIC
nd renal failure. Prompt diagnosis and adequate management
mprove clinical conditions in 1 to 4 weeks postpartum. Maternal
ortality ranges from 7% to 18% and foetal mortality from 9% to
3% [13,37,38].
The management of AFLP requires: (i) early recognition and
iagnosis, as the best maternal survival rate is when the interval
rom occurrence of AFLP to delivery is one week; (ii) aggressive
aternal stabilization in intensive care setting, adequate support-
ve therapy (diet low in fat and protein and high in carbohydrates,
lood components, plasma exchange and haemodialysis, broad-
pectrum antibiotics, correction of dehydration, electrolyte and
cid-base balance, treatments to protect the liver, reduce jaun-
ice, and diminish liver enzymes); (iii) rapid delivery: if vaginal
elivery cannot be achieved quickly, caesarean section is the pre-
erred method [37,38]. Breast-feeding is not contraindicated by
FLP itself, however this should be evaluated on the basis of the
upportive therapy needed for maternal stabilization in the inten-
ive care setting.
ISF expert panel recommendations:
Interval from AFLP onset to delivery should not exceed one
week (Class IIa, Level B), therefore prompt diagnosis is crucial.
In women  with AFLP, maternal stabilization should be per-
formed in an intensive care setting with prompt supportive
therapy (Class IIa, Level B).
When vaginal delivery cannot be achieved quickly in AFLP,
caesarean section should be performed (Class IIa, Level B).
. Liver disease occurring during pregnancy.1. Acute viral hepatitis
The most common cause of jaundice in pregnancy is acute viral
epatitis. The incidence of hepatitis in pregnancy varies greatly Disease 48 (2016) 120–137 123
throughout the world according to hygiene, sanitation and socio-
economic conditions [39].
Hepatitis A virus (HAV) is the most common cause of acute viral
hepatitis in the general population but its occurrence during preg-
nancy has been scarcely reported. Hepatitis A is not associated with
a severe outcome during pregnancy and vertical transmission is
very rare. In a recent study of the Korea University, 16,944 pregnant
women were reviewed retrospectively and 12 cases of acute HAV
infection were identiﬁed (0.07%). Among them, 4 patients (30%)
developed maternal complications, including cholestatic hepatitis
and preterm contraction. In only 1 case it was reported foetal ascites
and intra-abdominal calciﬁcations [40].
HAV vaccination should be considered particularly for women
living in areas of high endemicity and poor socioeconomic condi-
tions, to avoid maternal and foetal complications associated with
HAV infection in pregnancy. Since there is no evidence of HAV
vertical transmission with lactation, breast-feeding appears to be
safe.
Acute hepatitis B virus (HBV) infection is not associated with an
increased mortality or congenital malformations, although it can
cause spontaneous abortion in the ﬁrst weeks of pregnancy [41]. A
recent study involving 22 pregnant patients and 87 matched non-
pregnant controls investigated the clinical features and outcome of
acute hepatitis B in pregnancy [42]. No difference in mortality or
occurrence of fulminant hepatitis was found between the 2 groups.
Clinical recovery was also similar between pregnant and non-
pregnant women. However, signiﬁcantly higher levels of hepatitis
B surface antigen (HBsAg) and lower ant-HBs seroconversion rates
were found in pregnant patients than in non-pregnant patients,
indicating that pregnancy could be a risk factor for chronicity fol-
lowing acute HBV infection. Acute HBV infection in pregnancy has
a higher rate of vertical transmission than that usually occurring
during delivery, due to newborn exposure to cervical secretions
and maternal blood [43]. HBV vaccination and hepatitis B immune
globulin administration to newborns of HBsAg-positive mothers
represent the main strategy to prevent HBV vertical transmission
[44].
Acute hepatitis C virus (HCV) infection has been rarely reported
during pregnancy and is limited to high-risk groups, such as
intravenous drug users. Frequency of acute hepatitis C during
pregnancy is estimated between 0.4% and 6% [45]. Several case
reports can be found in literature and none of them reported
relevant adverse clinical outcome in pregnancy [46]. HCV infec-
tion can be vertically transmitted (risk from 3% to 5%), but there
is no evidence of increased transmission through breast-feeding
[47]. However antiviral treatment is contraindicated due to the
teratogenic effect of drugs available until recently [48] while no
data are available for the new interferon-free regimens in this
setting.
Hepatitis D virus (HDV) can be acquired by co-infection with
HBV or by super-infection of a HBV carrier [49]. Data regarding
acute hepatitis D and pregnancy are scant. Krajden et al. described a
case in a 18-year-old pregnant woman  (intravenous drug user) who
developed fatal fulminant hepatitis with massive hepatic necrosis
due to HBV and HDV co-infection [50]. Considering the availability
of HBV vaccination and the change in HDV  epidemiology, acute
hepatitis D in pregnancy appears to be only sporadic.
Hepatitis E virus (HEV) is responsible for major outbreaks of
acute hepatitis in developing countries. HEV is enterally trans-
mitted and clinical manifestations are similar to other forms of
viral hepatitis, except in pregnant women that are at greater
risk of developing fulminant hepatitis (25% mortality rate) [51]. A
recent study compared maternal and foetal outcomes in pregnant
women with acute viral hepatitis caused by HEV and other hepati-
tis viruses. Authors found that fulminant hepatic failure was more
common (relative risk, 2.7 [95% CI, 1.7–4.2]; p = 0.001) and maternal
124 Special Article / Digestive and Liver Disease 48 (2016) 120–137
Table 2
Clinical features of acute viral hepatitis in pregnancy.
Maternal complications Foetal complications Vertical transmission Prevention and treatment
HAV Mild gestational complications Rare Probable in perinatal period Vaccination
HBV  Same as general population Rare, preterm delivery 50–70% in III trimester Vaccination and prophylaxis
HCV  No No 3–5% Peg-IFN + RBV contraindicated
HDV  Same as general population n.a. n.a. HBV vaccination
HEV  Lethal (up to 25%) Preterm labour and stillbirth ∼50% No FDA-approved vaccine
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bAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatit
ibavirin.
ortality was greater (relative risk, 6.0 [95% CI, 2.7–13.3]; p < 0.001)
n HEV-infected women than in non-HEV-infected women. More-
ver, women with HEV infection had a higher risk of intrauterine
oetal death [52]. Vertical transmission rates are reported between
3.3% and 78.9% [53,54]. There is currently no evidence of HEV
ransmission through breast-milk. Table 2 summarizes the clinical
eatures of acute viral hepatitis and pregnancy.
ISF expert panel recommendations:
Vaccination is the most effective strategy for prevention of
HAV and HBV transmission (Class I, Level A). In addition, hep-
atitis B immune globulin must be administered to newborns
from HBsAg-positive mothers to prevent HBV vertical trans-
mission (Class I, Level A).
Currently, there is no FDA-approved vaccine to prevent HEV
infection. Considering the severe course of hepatitis E in preg-
nancy, particularly in countries with poor sanitation, early
delivery of the foetus should be considered to avoid maternal
complications (Class I, Level C).
Breast-feeding is not contra-indicated in case of maternal
acute viral hepatitis (Class I, Level B).
.2. Gallstone disease
Gallstones are common during pregnancy. The prevalence
anges between 2.5% and 11% of cases [45]. During pregnancy,
emale sex hormones are endogenously increased, and biliary
ludge (composed of cholesterol, calcium bilirubinate and mucin)
ppears in 5–30% of women [55]. In the post-partum period
ludge resolution develops in two-third of cases, small gallstones
microlithiasis) disappear in one-third, but deﬁnite gallstones
ecome established in approximately 5% of cases [56,57]. Addi-
ional risk factors include obesity, reduced high-density lipoprotein
holesterol and metabolic syndrome [55]. Another often under-
iagnosed condition may  be the low-phospholipid-associated
holelithiasis, which is associated to a genetic defect in the ABCB4
ene with loss of canalicular MDR3 protein and/or loss of protein
unction [58]. Most women with this genetic variant develop intra-
epatic cholestasis of pregnancy and eventually cholelithiasis.
Acute biliary colic or uncomplicated cholecystitis can be treated
onservatively with bed rest, intravenous ﬂuids, and antibiotics.
onservative treatment of cholelithiasis and its complications dur-
ng pregnancy is associated with recurrent biliary symptoms and
requent emergency department visits; thus ERCP and laparoscopic
holecystectomy should be considered [59]. The use of drugs such
s UDCA and the lipid-lowering compound ezetimibe could also
e considered [60]. ERCP can be performed safely during preg-
ancy and remains the ﬁrst-line modality for the management of
holedocolithiasis and its associated complications. While newer
echniques focus on avoiding the use of ﬂuoroscopy, their bene-
ts over traditional techniques employing minimal ﬂuoroscopy are
nclear [61]. Cholecystectomy during pregnancy is not entirely safe
ecause of the abortion risk with anaesthesia. In a retrospectiveirus; HEV, hepatitis E virus; n.a., not available; Peg-IFN, pegylated interferon; RBV,
study, however, surgical management of symptomatic cholelithi-
asis in pregnancy was  found to be safe and more useful than
conservative management in reducing the rate of labour induction
and preterm deliveries [62]. Laparoscopic cholecystectomy, when
indicated, should be performed in the second trimester to avoid
serious complications.
AISF expert panel recommendations:
• Biliary colic and acute cholecystitis during pregnancy should
be treated conservatively. ERCP should be considered in case
of choledocolithiasis and its complications (Class III, Level A).
• Laparoscopic cholecystectomy should be considered in
selected cases as second-line management in case of failure of
conservative management; when indicated, it should be per-
formed in the second trimester to avoid serious complications
(Class III, Level A).
3.3. Vascular liver diseases
In pregnancy, the levels of coagulation factors VII and VIII, von
Willebrand factor and ﬁbrinogen are increased, while free protein
S levels are reduced. Moreover, increased plasminogen activator
inhibitor-1 and 2 (the latter synthesized by the placenta) decrease
ﬁbrinolytic activity. Such changes shift the haemostatic balance
towards hypercoagulability, which persists up to 8 weeks after
delivery [63]. Therefore, it is not surprising that the vascular liver
diseases, in which thrombophilia often plays a major role, can occur
or worsen during pregnancy.
3.3.1. Budd–Chiari syndrome
Budd–Chiari syndrome (BCS) is a rare disease caused by the
obstruction of the hepatic venous outﬂow, due to thrombosis of
the hepatic veins or of the suprahepatic portion of the inferior vena
cava, leading to sinusoidal congestion, ischaemic liver damage and
portal hypertension [64,65].
One or more risk factors for venous thromboembolism are usu-
ally present in BCS patients. Pregnancy, as well as oral contraception
or oestrogen-replacement therapy, may  precipitate BCS [66–70].
BCS occurring in pregnancy accounts for about 15% of all women
with BCS [71]. Symptoms include fever, abdominal pain, ascites,
lower limb oedema, jaundice, gastrointestinal bleeding and hepatic
encephalopathy. In pregnancy, the clinical presentation is fre-
quently fulminant, with a high mortality.
Ultrasound is the imaging technique of choice in pregnancy
as there is no ionizing radiation exposure associated with it [72].
Computed tomography (CT) scan is contraindicated. The safety of
gadolinium-based contrast agents is controversial; therefore mag-
netic resonance imaging (MRI) should be used if the diagnosis of
BCS cannot be otherwise excluded (Class IIb, Level C).Besides few reports of BCS in pregnancy [66,68,73], a recent
study [74] investigated the maternal and foetal outcome of 43
women with BCS, seven of them with the disease presenting in
pregnancy. In these 7 women there were 3 miscarriages, 1 early
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reterm delivery, and 3 healthy newborns. Two women received
ranjugular porto-systemic shunt (TIPS) and one underwent ortho-
opic liver transplantation (OLT) within two months postpartum.
ll were alive after 57 ± 46 months from delivery.
The management of BCS occurring in pregnancy differs from that
n non-pregnant women as vitamin K antagonists (VKA) are con-
raindicated due to risk of foetal haemorrhage and teratogenicity
72]. A stepwise treatment, starting with a twice-daily low molecu-
ar weight heparin (LMWH), followed by TIPS in failures or relapses,
s recommended (Class IIa, Level C). Liver transplantation is possible
75]. Anticoagulation, with LMWH  or VKA, can be restarted 12 hours
fter delivery (or 24 hours after caesarean section). Breast-feeding
s contraindicated in women taking LMWH,  but not in those taking
KA, which are excreted inactive in maternal milk (Class I, Level C).
ISF expert panel recommendations:
Pregnancy may  precipitate BCS. The clinical presentation is
often fulminant. The treatment of BCS during pregnancy is the
same as in non-pregnant women except for the contraindica-
tion of VKA (Class I, Level C).
Management of women with BCS during pregnancy requires
a multidisciplinary team in tertiary referral centres (Class I,
Level C). Maternal outcome may  be good provided a step-
wise treatment is adopted (Class IIa, Level C). Foetal outcome,
although a matter of concern, can be good (Class II, Level C).
Due to the rarity of the disease, there is no data to support
further recommendations.
Breast-feeding is contraindicated in women  taking LMWH  and
allowed in women taking VKA (Class I, Level C).
.3.2. Acute extra hepatic portal vein obstruction
Acute extra hepatic portal vein obstruction (EHPVO) is the
udden, usually thrombotic, occlusion of the portal vein, variably
nvolving its intrahepatic branches or tributaries, mesenteric and
plenic veins. Thrombophilia and abdominal precipitating factors
ften coexist. However, and in contrast to BCS, pregnancy rarely
riggers EHPVO. Indeed, in three European series, pregnant women
ccounted for only 0–2% of patients [76–78].
Acute EHPVO often presents with abdominal pain, ascites or
ever. However, symptoms vary from almost asymptomatic to
ntestinal infarction, depending on the extension of the involve-
ent of the spleno-portal axis, particularly of the proximal roots of
he superior mesenteric vein.
As for BCS, Doppler ultrasound is the procedure of choice in
regnancy.
No data on maternal and foetal morbidity and prognosis in acute
HPVO are available. In acute EHPVO not occurring in pregnancy,
f early recognized and treated, a 75% rate of complete or partial
ecanalization is expected [79].
As in non-pregnant women, the treatment is based on anticoag-
lation with LMWH.  Anticoagulation can be restarted 12 hours after
elivery (or 24 hours after caesarean section) with VKA if breast-
eeding is desired (Class I, Level C).
ISF expert panel recommendations:
Pregnancy rarely triggers EHPVO. The treatment of EHPVO
occurring in pregnancy, is the same as in non-pregnant
women, except for the contraindication of VKA (Class I, Level
C). Due to the rarity of the disease, there is no data to support
further recommendations.
Breast-feeding is contraindicated in women taking LMWH,
and allowed in women taking VKA, (Class I, Level C). Disease 48 (2016) 120–137 125
4. Pregnancy in patients with pre-existing chronic liver
disease
4.1. Chronic hepatitis B
In women  with chronic HBV infection, immunological changes
typical of pregnancy may  cause an increase in HBV DNA levels
while alanine aminotransferase (ALT) remain normal or near nor-
mal. Mild exacerbations may  occur after delivery [80,81]. In clinical
practice, women  who are HBV-positive carriers should be coun-
selled regarding pregnancy both on and off treatment.
In all cases, indication to treatment according to current recom-
mendations should be considered and discussed with the patient
[82]. When ﬁbrosis is mild or absent, treatment can be delayed;
stopping antiviral drugs may  be considered in women currently
receiving treatment. Pegylated interferon (PEG-IFN) is contraindi-
cated during pregnancy. When treatment is indicated, tenofovir
is the drug of choice (see below); women  who  become pregnant
while receiving entecavir, adefovir or PEG-IFN, should be switched
to tenofovir, if treatment is indicated.
Vertical transmission of HBV infection is prevented by vaccine
and anti-HBs immunoglobulin administration to newborns within
12 hours after delivery [83]. This strategy is cost-effective [84].
However, newborns to HBeAg-positive mothers retain a 6–10% risk
of acquiring HBV infection, despite prophylaxis [83]. There is gen-
eral agreement that risk of immunoprophylaxis failure increases
with increasing maternal viral load. Most studies set the risk thresh-
old at a HBV DNA level of 107 IU/mL, although there is no consensus
on this point [85].
Administration of antiviral nucleos(t)ide analogues (NUCs)
active against HBV to mothers with high viral load has been exam-
ined in some studies, in order to establish the safety and efﬁcacy in
preventing vertical transmission.
4.1.1. Safety of NUCs in pregnancy
The Food and Drug Administration (FDA) recently released rules
that replace the current product letter categories – A, B, C, D and X
– to indicate the potential of a drug to cause birth defects if used
during pregnancy [86]. The new labelling system entails the use
of three subsections in the labelling, titled “Pregnancy”, “Breast-
feeding” and “Females and Males of Reproductive Potential” that
provide a summary of the risks of using a drug during pregnancy
and breast-feeding and a discussion of the supporting data.
Lamivudine, tenofovir and telbivudine have been administered
in pregnancy. Lamivudine was previously listed in class C; how-
ever, it was used extensively in human immunodeﬁciency virus
(HIV)-positive mothers as part of their antiretroviral treatment,
with no excess in reported birth defect rates [87]; tenofovir and
telbivudine were listed in class B. In 6 studies of HIV  type 1
and/or HBV-infected women  receiving tenofovir during pregnancy,
adverse events were mild to moderate; none were considered to
be tenofovir-related. Five studies that followed in utero tenofovir-
exposed infants showed no increased risk of growth or bone
abnormalities [88]. A long-term follow-up of babies born to moth-
ers treated with telbivudine conﬁrmed safety [89].
4.1.2. NUCs in preventing mother-to-child transmission from
highly viremic women
Lamivudine given from week 32 of pregnancy to mothers with
serum HBV DNA ≥109 IU/mL reduced the incidence of newborn
infection in a placebo-controlled trial [90]; however not all new-
borns received complete prophylaxis. A further meta-analysis of
six studies conﬁrmed the efﬁcacy of lamivudine [91]. One study
showed a rapid emergence of resistant variants [92].
Telbivudine was  administered to 135 HBeAg-positive women
starting from week 20 to week 32 of gestation; 94 women  served
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s control. All newborns received active and passive immuno-
rophylaxis. The incidence of perinatal transmission was 0% in
he treatment group vs. 8% in controls (p = 0.002) [93]. No seri-
us adverse events were reported. A meta-analysis of six studies
onﬁrmed the efﬁcacy of telbivudine in this context; however, the
uality of the studies was poor [94]. A further study in 648 moth-
rs receiving telbivudine or lamivudine or no drug (n = 252/51/345)
rom week 28 of pregnancy showed that both regimens were safe
nd superior to no drug [95].
Tenofovir was evaluated in three non-randomized, small-sized
tudies, both showing efﬁcacy in preventing newborn infection
96–98]. In a non-randomized study tenofovir given for 58 ± 19
ays before delivery was more potent than lamivudine [99].
Of note, the labels of NUCs recommend against their use during
reast-feeding. A recent paper reviewed the data on lamivudine
nd tenofovir and found that the exposure to the drugs is lower
uring breast-feeding than in utero [100].
Amniocentesis performed on HBsAg-positive mothers with
erum HBV DNA ≥107 copies/mL signiﬁcantly increased the fre-
uency of vertical transmission [101].
ISF expert panel recommendations:
All pregnant women  must be tested for HBsAg (Class I, Level A)
and if positive tested for HBeAg/antiHBe and HBV-DNA (Class
I, Level B). Early testing may  allow a better management of
HBsAg-positive women  (Class I, Level C). Early antiviral treat-
ment must be considered in the presence of advanced liver
ﬁbrosis (F3-F4); tenofovir is the preferred drug due to its high
genetic barrier, safety and potency; treatment must be con-
tinued after delivery (Class I, Level A).
Pregnant women  with serum HBV DNA ≥107 IU/mL should
receive antiviral treatment with a NUC to minimize the risk of
vertical transmission (Class II, Level B). Tenofovir or telbivu-
dine are the drugs of choice and should be started no later
than week 32 of gestation (Class I, Level B); lamivudine is also
allowed (Class II, Level B); treatment is stopped at week 0–4
after delivery. During breast-feeding, the safety of continuing
treatment is uncertain (Class II, Level C).
All newborns from HBsAg-positive mothers must receive
standard prophylaxis with vaccine against HBV and antiHBs
immunoglobulins within 12 hours after delivery (Class I, Level
A).
.2. Chronic hepatitis C
Hepatitis C is a major public health problem: worldwide more
han 200 million people are infected with HCV, with an over-
ll prevalence of 3.3%. The epidemiology of HCV varies among
ountries and its prevalence in pregnant women has not been
xtensively studied. The prevalence of anti-HCV positivity among
regnant women in Europe is estimated between 1.7% and 2.5%
45,102,103], but increases to 8% in some developing countries.
The natural history of liver disease in pregnant women and
heir offspring is not fully understood. Pregnancy does not seem
o modify the natural course of HCV disease: pregnant women are
enerally asymptomatic and during pregnancy a signiﬁcant reduc-
ion in ALT levels has been reported, with a rebound during the
ostpartum period, accompanied by HCV RNA increase towards the
nd of pregnancy in the majority of HCV-infected pregnant women.
owever, in different studies, which monitored viral load by
onthly testing, HCV RNA was stable during pregnancy in chronic
CV carriers without biochemical activity, whereas viremic ﬂares
ccurred in pregnant women with biochemical activity [46,104].
Few data are available about the impact of HCV infection on
ertility or pregnancy. Preliminary data suggest no increase in Disease 48 (2016) 120–137
spontaneous miscarriage rate or in obstetric complications in HCV-
infected women compared to controls. However, some studies
reported a decrease in newborn weight, an increase in congeni-
tal abnormalities and in preterm delivery rate [105,106]. Moreover,
retrospective data suggests a signiﬁcantly higher incidence of intra-
hepatic cholestasis of pregnancy in HCV-infected pregnant women
compared with controls.
Chronic hepatitis C can lead to vertical transmission of HCV,
while it only marginally inﬂuences the course of pregnancy and
seldom induces spontaneous abortion. The global rate of vertical
transmission of HCV is relatively low; it has been estimated
between 3% and 5% [107], in infants born from HCV-positive moth-
ers. Some studies suggest that perinatal transmission is limited to
viremic women, particularly if maternal viral load is higher than
100,000 UI/mL during delivery. Besides viral load, the risk of ver-
tical transmission increases in women co-infected with HIV, in
those abusing alcohol or drugs and after invasive procedures such
as amniocentesis, instrumented vaginal delivery and prolonged
ruptures of membranes (>6 hours). Delivery modalities do not
inﬂuence transmission, and caesarean section does not decrease
perinatal HCV transmission. Breast-feeding should not be dis-
couraged, as transmission of HCV by breast-feeding has not been
demonstrated [108].
HCV-infected pregnant women  do not need speciﬁc monitor-
ing; antiviral therapy for HCV is contraindicated during pregnancy
due to the potential teratogenic effects of ribavirin and the side
effects of PEG-IFN. No data are available regarding new interferon-
free regimens (Table 3). Treatment options should be offered before
pregnancy [109,110].
AISF expert panel recommendations:
• Pregnancy does not seem to modify the natural course of
HCV disease and chronic hepatitis C only rarely inﬂuences the
course of pregnancy (Class I, level B).
• The risk of vertical transmission increases in highly viremic
HCV-infected women, in those co-infected with HIV, or
abusing alcohol or drugs, or after invasive procedures (amnio-
centesis, instrumented vaginal delivery, prolonged ruptures
of membranes) (Class II, level A).
• Antiviral therapy for HCV is contraindicated during pregnancy
due to the potential teratogenic effects of ribavirin and the
side effects of PEG-IFN (Class I, level A). No data are available
about interferon-free regimens.
4.3. Autoimmune hepatitis
Autoimmune hepatitis (AIH) usually affects women in fertile
age, thus pregnancy is rather common in those patients. In a ret-
rospective German study the outcome of pregnancy was assayed
by a questionnaire obtained by 22 AIH patients with 42 pregnan-
cies [111]. Seven pregnancies (17%) were delivered pre-term before
week 36 of gestation, and the rate of adverse pregnancy outcome
was 26%. Of the 35 live births, 30 children showed a completely
normal development over a median observation of 56 months. One
child was  born with Smith-Lemli-Opitz syndrome, a rare autosomal
recessive disorder of cholesterol metabolism, and another devel-
oped tetraparesis after pre-term delivery. The cause of adverse
pregnancy outcome could be elucidated in 4 of 11 cases: one septic
abortion occurred in the week 19 of gestation. Another pregnancy
loss occurred in the week 18 of gestation, due to maternal fulminant
hepatic failure. One child was delivered by emergency caesarean
section at week 32 and died for congenital heart block. The same
mother delivered a second baby at week 24 and the baby had
Edward’s syndrome (trisomy 18) and died shortly thereafter [111].
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Table  3
Pharmacotherapy for hepatitis C virus infection during pregnancy and breast-feeding.
Drug FDA class Pregnancy Breast-feeding
Peg-Interferon  C There are no adequate and well-controlled studies of PEG-IFN
in  pregnant women. PEG-IFN is to be used during pregnancy
only if the potential beneﬁt justiﬁes the potential risk to the
foetus.
No data available.
Because of the potential for adverse reactions in nursing
infants, a decision must be made whether to discontinue
nursing or discontinue PEG-IFN treatment.
Ribavirin X There are no controlled data in human pregnancies.
Ribavirin-containing regimens are contraindicated in pregnant
women and in male partners of women  who  are pregnant.
Effective contraception (at least 2 reliable forms) is required
during ribavirin therapy and for at least 6 months after
therapy.
No data available.
Because of the potential for adverse reactions from the drugs
in nursing infants, a decision must be made whether to
discontinue nursing or discontinue Ribavirin treatment.
Telaprevir X Telaprevir combination therapy is contraindicated in women
who are or may  become pregnant and in the male partners of
women who are pregnant.
Nursing should be discontinued before starting therapy.
Boceprevir X Boceprevir combination therapy is contraindicated in women
who are or may  become pregnant and in the male partners of
women who are pregnant.
Nursing should be discontinued before starting therapy.
Sofosbuvir Ba Use should be avoided. Use should be avoided.
Simeprevir X Use should be avoided. Use should be avoided.
Daclatasvir X Use should be avoided. There are no data from the use of
daclatasvir in pregnant women therefore daclatasvir is not
recommended during pregnancy.
Use should be avoided. It is not known whether daclatasvir is
excreted in human milk. Mothers should be instructed not to
breastfeed if they are taking daclatasvir.
Ledipasvir Ba Use should be avoided. This drug should be used during
pregnancy only if the beneﬁt outweighs the risk to the foetus.
Effective
Use should be avoided. It is not known whether ledipasvir is
excreted in human milk. Developmental and health beneﬁts of
breast-feeding should be considered as well as the mother’s
clinical need for the drug; potential side effects in the
breastfed child due to the drug or the mother’s underlying
condition should be considered.
Viekira Packb Ba Not recommended for use during pregnancy. Use should be avoided. It is not known whether Viekira Pack
drugs are excreted in human milk. Mothers should be
instructed not to breastfeed if they are taking dasabuvir.
PEG-IFN, peginterferon.
a In association with ribavirin, to be considered FDA class X.
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An English study reported the outcome of pregnancy in 53
omen with 81 pregnancies [112]. Six pregnancies were conceived
y in vitro fertilization; 20% of pregnancies were delivered pre-
erm. The live birth rate was 73% (59/81). Of the remaining 22
onceptions, there were 8 spontaneous miscarriages (10%), 12 ter-
inations of pregnancy, 1 stillbirth and 1 foetal death due to an
nexpected maternal death. Two of the live birth children had
bnormalities: one had cerebral palsy and the other developed
erthes’ disease of the hip. The presence of maternal cirrhosis
mpacted on foetal outcome, and the live birth rate was lower in
others with liver cirrhosis at the time of conception (p = 0.002).
A Brazilian study reported a retrospective analysis of 54 preg-
ancies in 39 AIH patients [113]. The rate of pre-term delivery
as 11.8% and the foetal loss rate was 29.4%. One woman  expe-
ienced a tubal ectopic pregnancy. One twin pregnancy and one
ull-term pregnancy were delivered via emergency caesarean sec-
ion because of acute foetal distress without neonatal death. One
regnancy resulted in a stillbirth secondary to an anencephalic foe-
us; another women delivered a baby with uretral stenosis.
The maternal course is highly variable. In case of pregnancy
ccurring at presentation of AIH with “acute” onset, liver disease
ay  have a fulminant course and the foetus has a low chance of sur-
ival [114]. In general, women who reach disease remission and do
ot have cirrhosis with portal hypertension, have a high chance
f a favourable pregnancy outcome [115]. In general, pregnancy
onfers a beneﬁcial effect on immunosuppression with a reduction
n maintenance therapy. This is due to several factors, including
he physiological increase of serum cortisol [116,117]. In clinical
ractice the dosage of steroids to maintain remission should be
educed in case of pregnancy. However, pregnancy-related ﬂares
ay  occur in up to 21% of cases (Supplementary table S4), whereas
he probability of fares is highest after delivery with an incidenceas high as 40% [118]. Table 4 reports the recommendations of phar-
macotherapy for AIH during pregnancy and breast-feeding.
AISF expert panel recommendations:
• Treatment options should be discussed before pregnancy in
patients with AIH. If the patient is receiving steroid monother-
apy the dosage needed to maintain remission will likely be
lower. As pregnancy-related ﬂare may  occur, a reasonable rec-
ommendation is to increase the steroid dose shortly before
the expected date of delivery, and to monitor liver enzymes
and IgG closely in the weeks following delivery (Class II-III,
Level A).
• In case of combined treatment with steroids and azathio-
prine, azathioprine can be discontinued although the risk of
stillbirth and/or foetal malformation is negligible. In case of
azathioprine monotherapy there is a risk of ﬂare after ther-
apy withdrawal; thus maintenance therapy with azathioprine
should be continued strictly monitoring liver enzymes (Class
III, Level A).
• During the breast-feeding period only steroids can be used
(Class III, Level A).
4.4. Primary biliary cholangitis
Primary biliary cholangitis (PBC) generally develops near
menopausal age, with a broad range that includes both the fer-
tile and the geriatric ages. Pregnancies are rather uncommon after
PBC has been diagnosed, and there are limited reports in the lit-
erature speciﬁcally focusing on the outcome of pregnancy in PBC
patients, as well as on the effect of pregnancy on PBC course. There
is only one report dealing on the onset of PBC during pregnancy
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Table 4
Pharmacotherapy for autoimmune hepatitis during pregnancy and breast-feeding.
Drug FDA class Pregnancy Breast-feeding
Prednisone or Prednisolone C Should be used monitoring the dosage Excreted into the breast milk but in such low doses
that no effect to the child can be expected
Budesonide C Clinical experience is scant, should only be used under
strict indication
No data available
Azathioprine D Should be used under strict indication and monitoring
the dosage
Use should be avoided
Tacrolimus Should not be used without special risk evaluation,
little clinical experience
Use should be avoided
Cyclosporine C Clinical experience is scant, but animal studies indicate
that is safe, could be used if the advantage to the
 to the
Excreted into breast milk, risk of adverse effects on the
newborn cannot be excluded
[
a
i
o
a
2
s
P
s
d
s
t
a
L
p
n
f
t
a
w
h
o
p
p
t
w
p
6
c
a
c
a
r
n
e
i
b
e
A
•
•mother is greater than the risk
Mycophenolate Mofetil C Use should be avoided 
Metothrexate X Use should be avoided 
119], in a 47 year-old Japanese woman who developed jaundice
t the 24th week of pregnancy. Information on PBC and pregnancy
n the literature have been obtained by a questionnaire method-
logy. In particular, the National Health and Nutrition in the USA
dministered a standardized questionnaire to 182 PBC patients and
25 age- and sex-matched controls [120]. The results of this study
howed that there were signiﬁcantly more pregnancies among the
BC cases than among controls. This study, however, presented
everal limitations: there was no conﬁrmation of the self-reported
ata, nor information on the timing of pregnancies, and bias in the
election of the control group. A recent retrospective study iden-
iﬁed 32 women (50 pregnancies) who either became pregnant
fter PBC diagnosis or in whom pregnancy led to diagnosis [121].
iver biochemistry remained stable in 70% of patients throughout
regnancy, no adverse maternal events were observed during preg-
ancy or post-partum, and only 6% developed progressive disease
ollowing delivery [121]. Finally, the outcome of pregnancy and
he inﬂuence of pregnancy on the course of PBC were analyzed in
 case–control study including 186 consecutive patients with PBC
ho had at least one conception and a 1:2 control group of 367
ealthy women [122]. The two groups’ history was similar in terms
f miscarriages, voluntary interruption of pregnancy, and term and
re-term deliveries. Pruritus during pregnancy was recorded in 15
regnancies involving 13 PBC patients (3%) and in none of con-
rols. Perinatal and postnatal deaths and complications at childbirth
ere only recorded in the PBC patients, involving 11 babies (2.7%,
 < 0.05). Eight pregnancies occurred after PBC was diagnosed in
 patients, all of whom had a favourable course at term, with no
omplications at childbirth.
UDCA is safe and well tolerated during pregnancy. A report from
 French group described 6 patients with PBC having 9 pregnan-
ies: their UDCA treatment was withdrawn in the ﬁrst trimester
nd restored during the second and third [123]. All the women
emained asymptomatic and their liver function tests fell within
ormal range for a normal pregnancy, and there were no deliv-
ry issues or childbirth complications [123]. UDCA treatment with
ncreasing doses up to 25 mg/kg/day during breast-feeding has
een shown to be safe, and no adverse effects were observed in
ither infants or mothers [124].
ISF expert panel recommendations:
Pregnancy in PBC patients in the pre-cirrhotic stage (his-
tological stage I-III) has a favourable outcome and there is
no contraindication for pregnancy continuation (Class III,
Level A).
In patients with PBC in the cirrhotic stage pregnancy and deliv-
ery must be monitored for the potentially higher than normal
risk of complications both due to portal hypertension and
child birth complications (Class III, Level A). offspring
Use should be avoided
Use should be avoided
• UDCA should be continued at standard dosage during preg-
nancy and breast-feeding (Class III, Level A).
4.5. Primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) has an incidence around
0.9–1.3 per 100,000 per year and a prevalence around 8.5–14.2 per
100,000 in Northern Europe and in the United States [125]. Up to
80% of PSC patients have concurrent inﬂammatory bowel disease
(IBD) [125]. Fertility does not seem to be reduced in patients with
PSC, and in young female patients pregnancy is possible.
No strong association has been found between the development
of PSC and previous perinatal events including birth length, breast-
feeding and the majority of maternal medical complications [126].
Thirteen pregnancies in 10 patients with PSC were observed in
Sweden [127]. Seven patients had PSC before pregnancy, 2 devel-
oped PSC during pregnancy, and one patient developed PSC 2
months after a normal pregnancy with a normal delivery. No foetal
loss occurred, the outcome of all neonates was normal and liver
tests did not change during pregnancy. However, the symptoms
related to PSC, and in particular pruritus and abdominal pain, wors-
ened in several affected women, and in one case this brought to
preterm birth [127].
A case report described a 36-year-old woman with PSC who
became pregnant after developing dominant stricture [128]. A
healthy baby boy was delivered at 33.5 weeks. The mother required
cholangiography and stent placement immediately after delivery,
but her post-partum course was  otherwise unremarkable.
Another case report showed an improvement in liver function
during pregnancy and deterioration after pregnancy, suggestive of
autoimmune aetiology [129].
The largest series of patients (n = 17) with PSC having at least
one pregnancy was reported in Germany [130]. Despite a frequent
rise in serum liver tests, no serious maternal complications were
observed. Two pregnancies were delivered pre-term and 4 foetal
losses occurred early in pregnancy. Continuation of treatment with
UDCA or azathioprine had no negative effects on pregnancy out-
come.
The exacerbation of IBD during pregnancies complicated by PSC
is described in 25–30% of cases [127]. PSC also carries a risk of bil-
iary sludge and stones; nevertheless, the risk of biliary colic and/or
complications of gallstones is very low.
AISF expert panel recommendations:
• Pregnancy is not contraindicated in patients with PSC; the risk
of unfavourable course, is correlated with the degree of portal
hypertension. The increased risk of preterm birth and foetal
demise associated with high foetal bile acid levels suggests the
need for close foetal monitoring (Class II-III, Level A).
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UDCA should be continued at a standard dose during preg-
nancy, steroids can be used for management of both PSC and
IBD, if present (Class II, Level A). UDCA should also be contin-
ued during breast-feeding (Class II, Level A).
Possibly avoid azathioprine, although the risk of stillbirth
and/or foetal malformation is negligible (Class III, Level A).
.6. Genetic disorders
.6.1. Hereditary hemochromatosis
Hereditary hemochromatosis (HH) is a recessive disease (preva-
ence 2–5/1000) due in most of the cases to homozygosity for the
282Y mutation of HFE gene, which confers a genetic predisposi-
ion to progressive body iron overload. Host-related and acquired
actors are needed for the phenotypic expression of the disease.
Fertility is impaired only if diagnosis and treatment are late,
hen women have developed gonadal dysfunction. Given the
ecessive pattern of inheritance, there is no need for prenatal diag-
osis for pregnant women with HH [131].
A normal pregnancy usually mobilizes about 1 g of iron from
he mother’s body to allow expansion of the blood volume and
rovide iron to the foetus, thus mild anaemia is frequent in preg-
ancy, and iron supplementation is frequently prescribed. Iron
hould not be prescribed routinely to pregnant women  with HH
nless clearly iron deﬁcient, and ferritin should be frequently
hecked.
In the presence of iron overload, iron depletion by phlebotomy
r chelators should be delayed to the end of pregnancy, unless
vident cardiac involvement is present.
Gestational diabetes seems to be more frequent in pregnant
omen heterozygous for the C282Y mutation [132].
ISF expert panel recommendations:
No special care for pregnant women  with hereditary
hemochromatosis is needed, except for cases of juvenile
hemochromatosis or in women who developed cirrhosis.
Phlebotomies in pregnant women with hereditary hemochro-
matosis should be delayed to the end of pregnancy (Class III,
Level A).
.6.2. Wilson’s disease
Wilson’s disease is a recessive disease (prevalence 1/30,000)
haracterized by defective biliary excretion of copper and conse-
uent accumulation in liver and brain, due to rare mutations of
TP7B gene, which encodes a copper transporting protein. Clinical
resentation, which can occur at any age, may  be very different
ncluding acute and chronic liver disease, cirrhosis, neuropsychi-
tric disorders, and acute haemolysis.
Women  are frequently non ovulatory, but treatment can restore
ertility when started in an early stage of the disease. Successful
reatment allows pregnancy but copper status should be optimized
efore pregnancy. Likelihood of delivering a homozygote, without
nowledge of the paternal status, is 0.05% [133].
Maintaining therapy during pregnancy is essential because
nterrupting the drugs has been associated with haemolytic
pisodes, hepatic insufﬁciency and maternal death. d-
enicillamine is safe, although the drug is teratogenic in animal
tudies, and there are reports of neonates with cutaneous abnor-
alities. In patients on D-penicillamine therapy, the dose should
e reduced by 25–50% of the pre-pregnancy dose to reduce foetal
isks. The ideal regimen is 750 mg  to 1 g of either D-penicillamine
r trientine during the ﬁrst two trimesters and 0.5 g in the
ast trimester. There is no evidence that zinc sulfate or acetate
ncreases the risk of foetal abnormalities. Therefore, therapy
hould be continued at regular doses. All patients with Wilson Disease 48 (2016) 120–137 129
disease should be offered genetic counselling when consider-
ing pregnancy and offspring should always be screened for the
disease [133–135].
AISF expert panel recommendations:
• All patients with Wilson disease should be offered genetic
counselling when considering pregnancy and offspring
should always be screened for the disease. Copper status
should be optimized before pregnancy. Maintaining therapy
during pregnancy is essential with reduced doses of chelators
compared to the pre-pregnancy period (Class II-III, Level B).
4.6.3. Porphyrias
Porphyrias can present as acute or chronic disease. The inheri-
tance pattern is usually autosomal dominant, with low penetrance,
and trigger factors are needed for the disease to become appar-
ent. Prevalence ranges from 0.5 to 10/100,000 for acute porphyrias
(acute intermittent porphyria, variegate porphyria and hereditary
coproporphyria), with polymorphous clinical presentation that can
be life-threatening. A prevalence of 1/25,000 is known for porphyria
cutanea tarda. This is the most frequent of chronic porphyrias
and usually presents with cutaneous symptoms, while porphyria
variegata and hereditary coproporphyria may  also present neu-
ropsychiatric symptoms.
Acute porphyrias usually manifest after puberty, more fre-
quently in women  with a peak in the third decade [136]. Attacks
occur particularly during periods of hormonal change (e.g., luteal
phase of the menstrual cycle, and during oral contraceptive use).
Pregnancy is not contraindicated, although attacks are more fre-
quent during early weeks of gestation, potentially causing maternal
and foetal problems, and in the immediate postpartum period.
Recurrent attacks may  occur during pregnancy in patients with
acute intermittent porphyria, variegate porphyria, or hereditary
coproporphyria. Porphyria cutanea tarda may  present for the ﬁrst
time during pregnancy.
In a population-based study, pregnant women with the herita-
ble form of porphyria cutanea tarda or with active acute porphyria
had a signiﬁcant excess risk of prenatal death, low birth weight
and premature delivery [136]. Most commonly no speciﬁc therapy
for acute porphyrias is required during pregnancy. In case of acute
attacks, standard therapy with glucose infusion (200–500 g/day)
and heme arginate (4 mg/kg/day) is recommended for 3–4 days.
The list of potentially safe and unsafe drugs is reported at: www.
drugs-porphyria.org.
AISF expert panel recommendations:
• In women with acute porphyrias pregnancy is not contraindi-
cated although attacks may  exacerbate in periods of hormonal
changes, Pregnant patients with acute porphyrias should be
referred to a porphyria reference Centre for follow up (Class
III, Level A).
4.6.4. Glycogen storage diseases
Glycogen storage diseases (GSD) are very rare inherited reces-
sive metabolic diseases (prevalence 3–6/100,000) caused by defects
of enzymes involved in glycogen storage and disposal. Al least 15
types have been identiﬁed with some involving primarily the liver
and others the skeletal muscle. Initially considered an almost uni-
versally fatal disease, nowadays GSD are conditions, which allow
women to grow into adulthood and potentially become pregnant.
Presentation is strongly dependent on the type of disease, and
is characterized by severe hypoglicemia, and/or muscle symp-
toms. Long-term complications (hepatic adenoma often correlated
to polycystic ovaries, nephropathy, and cardiomyopathy) can be
delayed or prevented with optimal metabolic control.
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Despite high prevalence of irregular menstrual cycles and poly-
ystic ovaries, no fertility impairment was detected in women with
SD type Ia/Ib, and IIIa/IIIb, the two more prevalent GSD, which
nvolve the liver. Hepatic adenomas and nephropathy (in particular
n women with albuminuria) are the main risks of pregnancy.
Good metabolic control prior to conception and maintained
hroughout gestation directly correlates with successful outcome
n women with GSD [137,138].
ISF expert panel recommendations:
In women  with glycogen storage diseases good metabolic con-
trol prior to conception and throughout gestation is essential
since directly correlates with successful outcome (Class III,
Level B).
.7. Metabolic disorders
.7.1. Alcoholic liver disease
Pregnancy in alcoholic liver disease (ALD) presents two  main
roblems: liver damage and alcohol intake, including the effects of
lcohol on other organs and alcohol dependence, itself [139].
ALD comprises a large spectrum of alcohol-related liver dis-
ases, ranging from fatty liver or simple steatosis to alcoholic
epatitis, chronic hepatitis with hepatic ﬁbrosis or cirrhosis.
Pregnancy data are scarce in women with ALD, as women with
LD are often infertile. ALD leads to anovulation and amenorrhea
ue to many factors including disturbed oestrogen and endocrine
etabolism [140]. When pregnancy is successful in a cirrhotic
oman, spontaneous abortion rate, risk of prematurity, and peri-
atal death rate are all increased [141].
Alcoholic cirrhotic patients have a high risk of liver decompen-
ation because of worsening synthetic liver function, development
f ascites, and hepatic encephalopathy with high maternal mortal-
ty [141,142]. Maternal prognosis depends on the degree of hepatic
ysfunction during pregnancy rather than its cause [143]. Por-
al hypertension worsens during pregnancy because of increased
lood volume and ﬂow. Portal pressures can also increase because
f an increased vascular resistance due to external compression of
he inferior vena cava by the gravid uterus. Up to 25% of patients
ith varices have a bleeding episode during pregnancy [45]. The
reatest risk is in the second trimester, when portal pressures peak
142]. All patients with cirrhosis should undergo variceal screening.
anding before pregnancy, although not proven, is appropriate for
igh-risk varices (moderate evidence; weakly positive recommen-
ation). Finally, although there are no good studies evaluating the
mpact of vaginal delivery on the risk of variceal bleeding, it is rec-
mmended that patients have caesarean section to avoid increased
training [144]. Caesarean section is more common in women  with
LD, but one cannot rule out that the liver disease contributed to
he choice (very low evidence; weakly negative recommendation).
Concerning the effects of alcohol on other organs, is important
o mark that during pregnancy maternal heart rate and cardiac out-
ut increase, while blood pressure and systemic vascular resistance
ecrease. These alterations mimic  physiological changes in patients
ith decompensated chronic liver disease. Blood volume increases
y about 50%, peaking in the second trimester. However, blood ﬂow
o the liver remains constant during pregnancy.
Alcohol consumption during pregnancy has been linked to poor-
irth outcomes and long-term cognitive and behavioural deﬁcits
145]. Abusive and heavy drinking are associated with foetal alco-
ol syndrome (FAS), which includes growth retardation, central
ervous system damage, neurodevelopmental delays and facial
alformations [146]. Epilepsy is often reported in children with
AS [147]. Even in the absence of FAS, heavy alcohol consumption
uring pregnancy is correlated with adverse outcomes, including Disease 48 (2016) 120–137
miscarriage, stillbirth, preterm delivery and small-for-gestational
age (SGA) birth [148].
Data on disease frequencies in children born to mothers with
ALD do not exist, although prenatal alcohol exposure may  neg-
atively affect the foetus [147]. However, convincing evidence of
adverse effects related to low to moderate prenatal exposure to
alcohol is lacking [149]. Studying amount and timing of alcohol
intake during pregnancy is complicated by recall bias and by socio-
economic and life-style confounding such as cigarette smoking and
underreporting of drinking during pregnancy.
Women  hospitalized with ALD have an increased risk of
adverse pregnancy outcomes, including preterm and SGA  birth. The
increased risk of preterm birth could be attributed to alcohol intake
during pregnancy, but also to chronic liver disease per se. Chronic
liver disease is associated with increased levels of inﬂammatory
cytokines, which may  increase the risk of preterm birth [150]. A
Danish study found that alcohol consumption below four drinks
per week did not increase the risk of preterm birth. Women  in that
study, who consumed 2–3.5 drinks per week, had a 20% reduction in
risk [151]. Several recent studies found that alcohol is a risk factor
for preterm birth [152,153] (moderate evidence; weakly positive
recommendation).
There is a nearly 40% increase in risk of stillbirth for women
with ALD diagnosed before pregnancy. However, the numbers of
stillbirth were few and did not reach statistical signiﬁcance in the
adjusted models. Data should therefore be interpreted with caution
(very low evidence; weakly negative recommendation).
Several studies have been conducted to investigate whether
alcohol intake during breast-feeding can cause damage to the baby.
In fact, there was  no difference in the scores of cognitive devel-
opment, while a small but signiﬁcant difference, was  detected in
motor development of children [154] (low evidence; weakly posi-
tive recommendation).
Benzodiazepines seem the most recommendable option for
managing alcohol withdrawal, and psychosocial interventions suc-
ceed in reducing alcohol consumption or in maintaining abstinence
in alcohol-dependent pregnant women  [155] (moderate evidence;
weakly positive recommendation).
AISF expert panel recommendations:
• ALD was associated with adverse pregnancy outcomes, espe-
cially among women diagnosed before delivery (Class III, Level
A).
• Screening for alcohol use in antenatal care could identify
high-risk women and thereby prevent pregnancy and birth
complications (Class III, Level A).
• Alcohol consumption during pregnancy is contraindicated;
breast-feeding in women  with or without pre-existing liver
disease is contraindicated (Class III, Level B).
4.7.2. Non-alcoholic liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease worldwide. It is the hepatic expression of the
metabolic syndrome (MS) and shares the risks associated with its
components. However, very few studies have addressed the con-
cerns related to pregnancy in NAFLD. It is difﬁcult to ascertain from
available data whether pregnancy may  play a role in presentation
or deterioration of pre-existing NAFLD. In a small series from UK
[156], pregnant women  with chronic (at least 29 weeks) abnormal
liver function tests during pregnancy were screened for potential
hepatic disorders, both related and unrelated to pregnancy. In 5
women all known aetiologies were excluded; further evaluation
by liver ultrasound showed a variable degree of fatty liver and
conﬁrmed the diagnosis of NAFLD, associated with increased BMI.
None of them had pre-eclampsia nor gestational diabetes (GDM)
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uring pregnancy. The presence of NAFLD did not affect the mater-
al and neonatal outcomes. However, liver function tests usually
eteriorated after delivery. Pregnancy is associated with a 50–60%
ecrease in insulin sensitivity during physiological gestation [157]
nd NAFLD is driven by insulin resistance. The duration of the
regnancy-related insulin resistance, albeit very short, could have a
linical impact on NAFLD in susceptible individuals. However, with
he increase in age and BMI  observed in pregnancy [158,159], this
ssociation may  be casual rather than causal. Although there are
o speciﬁc studies considering the impact of NAFLD on maternal
nd foetal outcomes, some data can be inferred from the literature
n obese and diabetic pregnant women, given the extremely high
revalence of NAFLD in obesity and type 2 diabetes.
Obesity, metabolic syndrome and pregnancy. Obesity affects
early one-third of women at the child-bearing age in West-
rn countries [159]. Obesity and pregnancy are independently
ssociated with insulin resistance and inﬂammatory changes,
hich may  be exacerbated when these two conditions are com-
ined [157]. Consequently, overweight and obese women  are at
ncreased risk of metabolic dysfunctions during pregnancy. Indeed,
bese women have a 10–15% increased risk for pre-eclampsia
160] and are at higher risk to develop GDM [161]. Furthermore,
asal triglycerides and cholesterol concentrations increase two to
hree-fold with advancing gestation along with an increase in free
atty acid levels related to the decreased ability of insulin to sup-
ress lipolysis. Notably, these elevations are more pronounced in
regnant women with GDM [157]. These alterations in glucose and
ipid metabolism play a major role in excessive foetal growth and
diposity [162].
As described above, pregnancy can be considered a metabolic
tress test for the future risk of the MS.  Indeed, although these
regnancy-related dysmetabolic conditions most likely resolve
fter delivery, these women still have a subclinical metabolic dis-
rder and are at increased risk for the development of MS  later in
ife, particularly when associated with an increased post-partum
eight [163]. Since women with a history of GDM are at higher risk
f developing type 2 diabetes and NAFLD, a recent English study
164] evaluated the prevalence of ultrasound-diagnosed NAFLD
fter 10 years from delivery in a cohort of 110 non-diabetic women
ith previous GDM, compared with 113 women without previ-
us GDM. There was no signiﬁcant difference in BMI  in women
ith previous GDM compared with those without (28.9 ± 0.6 vs.
7.9 ± 0.6 kg/m2, respectively; p = 0.12), however women with pre-
ious GDM showed higher waist circumference (89 ± 1 vs. 84 ± 1
n controls, p = 0.002). The prevalence of metabolic dysfunctions
i.e. higher fasting and 2 h glucose concentrations following a 75 g
ral glucose tolerance test, dyslipidemia, insulin resistance-HOMA
ndex), was higher in women with previous GDM. Not surpris-
ngly, also the prevalence of NAFLD was greater in women with
revious GDM compared with those without (38% vs 17%, respec-
ively, p = 0.001), with an odd ratio (OR) of 2.77 (95% CI 1.43–5.37,
 = 0.002), after adjustment for BMI. These results may  be consis-
ent with NAFLD preceding type 2 diabetes. However, long-term
rospective studies are required to conﬁrm these data.
As a result of increasing maternal age, a higher proportion of
omen older than 40 years of age may  start pregnancy with central
at accumulation. Although lean and obese pregnant women  gain
imilar fat mass, in the latter there is a preference to store fat in
ctopic sites, particularly in the visceral area [165], with concomi-
ant lipotoxicity. Lipotoxic effects in pregnancy include maternal
ndothelial dysfunction, decreased trophoblast invasion and neg-
tive inﬂuences on placental metabolism and function, leading to
otential miscarriages and adverse pregnancy outcomes, such as
reeclampsia, preterm delivery and neonatal morbidity [166].
Obesity, metabolic syndrome and neonatal outcomes. There is
ow growing evidence that maternal obesity, GDM and the foetal Disease 48 (2016) 120–137 131
nutritional environment may  contribute to the offspring’s risk of
developing juvenile obesity and metabolic disorders. Foetal and
neonatal life are characterized by extraordinary plasticity and abil-
ity to respond to environmental stimuli by altering gene expression
via epigenetic modiﬁcations, i.e. covalent modiﬁcations to DNA
and chromatin that alter gene transcription independently of DNA
base sequence. The foetal exposure to excess lipids or to GDM
determines epigenetic modiﬁcations of genes involved in glucose
and lipid metabolism, leading to multiple metabolic alterations in
the foetus, newborn and possibly in the adult offspring [167,168].
Moreover, excess maternal lipid supply in utero, coupled with
the reduced oxidative capacity of the foetal liver, can promote
hepatic steatosis, mitochondrial dysfunction, oxidative damage
and inﬂammation, perhaps priming the liver to a later development
of NAFLD and to its progression to non-alcoholic steatohepati-
tis (NASH) [169,170]. Similarly, elevated maternal consumption of
fructose-sweetened beverages seems to potentiate the susceptibil-
ity of the offspring to develop future metabolic disturbances and
hepatic steatosis [171]. Whether these alterations could be fur-
ther promoted in the setting of an obesogenic environment (i.e.
chronic intake of high-fat/high-sucrose diets and sedentary habits),
or whether they could be reverted by a healthy lifestyle is of great
importance, but has to be ascertained.
Very recently, the results of a multicentre randomized trial,
aimed to determine the effect of antenatal dietary and lifestyle
interventions on neonatal outcomes in overweight and obese
pregnant women, have been published. A cohort of 2152 pregnant
women and 2142 liveborn infants were included: although there
were no differences in pregnancy, infants born to women following
lifestyle advice were signiﬁcantly less likely to have birth weight
above 4.5 kg or respiratory distress syndrome and showed a shorter
length of postnatal hospital stay, compared to infant born to women
who received standard care [172]. The prolonged and constant
follow-up on this population will clarify the long-term beneﬁts on
the risk of child obesity and metabolic derangements.
NAFLD and the polycystic ovary syndrome. Among the con-
ditions associated with NAFLD, the polycystic ovary syndrome
(PCOS) deserves particular attention. PCOS affects 6–25% of
reproductive-aged women and is associated with reproductive
complications, including oligo/amenorrhea and sub-fertility, and
metabolic derangements, such as insulin resistance, diabetes,
hypertension, dyslipidemia [173]. PCOS has recently been recog-
nized as a potential risk factor for NAFLD [174]. Although screening
has not been recommended, clinicians should be aware that female
patients with PCOS may  develop NAFLD and its progressive form,
NASH, even at younger age; childbearing NAFLD women with
reproductive problems may  have an underlying PCOS [175].
Early diagnosis of these two associated conditions, is mandatory
to ensure a multidisciplinary approach.
AISF expert panel recommendations:
• NAFLD should be considered in the differential diagnosis of
abnormal liver function tests during pregnancy. Pregnant
women with NAFLD should undergo screening for GDM
and should be carefully monitored for the development
of gestational hypertension, especially those who  are over-
weight/obese. After delivery, these women should be referred
to a hepatologist for management of their liver disease (Class
IIa, Level C).
• Women  with a history of GDM should be clinically monitored
because of their increased risk to develop NAFLD, in addition
to metabolic derangements (Class IIb, Level C).
• Women  with NAFLD, especially those who  are over-
weight/obese or have features of the metabolic syndrome,
should receive antenatal lifestyle counselling to reduce the
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risk of adverse maternal and neonatal outcomes and of future
metabolic alterations in the offspring (Class IIb, Level C).
Clinicians should be aware of the association between PCOS
and NAFLD and should consider performing liver ultrasound
and liver function tests in women  with PCOS, particularly
in those with features of the metabolic syndrome (Class IIa,
Level C).
.8. Vascular disorders
.8.1. Budd–Chiari syndrome (BCS)
Recent data [176] refer to sixteen women (24 pregnancies)
ith compensated BCS at conception, followed at three European
entres. Anticoagulation was administered during 17 pregnancies.
oetal loss before week 20 occurred in seven of 24 pregnancies
29%). Two pregnancies resulted in very preterm births (between
eeks 20 and 31) of one stillbirth and one infant with low
irth weight. Eleven pregnancies resulted in moderately preterm
irths (between weeks 32 and 36) of 11 infants with a favourable
utcome, although 3 were small for gestational age and 1 had
evere respiratory distress syndrome. Finally, four pregnancies
esulted in four infants at 37 or more gestation weeks, all with a
avourable outcome. Out of the 17 pregnancies reaching gestation
eek 20, there were nine vaginal deliveries and eight caesarean
ections.
Bleeding at delivery occurred in six women who  were on
nticoagulant treatment. Ascites recurred in two, because of
ortal thrombosis and TIPS occlusion, respectively, despite anti-
oagulation. Other maternal complications, unlikely related to
CS, including intrahepatic cholestasis, intrauterine haematoma,
reeclampsia and placenta praevia, occurred in 9 of 16 women.
A favourable pregnancy outcome, deﬁned as live birth at 32
r more weeks of gestation, with a healthy infant and no serious
bstetrical complication, occurred in half of the 24 pregnancies. All
omen were alive after a median follow-up of 34 months.
ISF expert panel recommendations:
Pregnancy is not contraindicated in women with BCS in stable
condition, since maternal and foetal outcome (beyond week
20 of gestation) are good (Class IIa, Level C). However, maternal
morbidity is increased (Class I, Level C). The risk-beneﬁt ratio
of anticoagulation is unclear.
Breast-feeding is contraindicated in women taking LMWH,
but not in women  taking VKA, which are excreted inactive in
maternal milk (Class I, Level C).
.8.2. Chronic-extra hepatic portal vein obstruction
In chronic extra-hepatic portal vein obstruction (EHPVO), the
ortal vein trunk is replaced by a cavernoma, a network of hep-
topetal, small venous vessels bypassing the obstructed portal vein
nd variably extending into the liver.
Main features of chronic EHPVO are recurrent bleeding from
esophago-gastric varices, splenomegaly with hypersplenism and,
arely, jaundice due to portal hypertensive biliopathy, or ascites.
hronic EHPVO can be asymptomatic. Liver function is normal or
lightly altered. Ultrasound is adequate to identify the cavernoma,
ortal vein collaterals and splenomegaly.
Portal hypertension increases in pregnancy. Variceal bleed-
ng is reported in 15% of pregnant women with chronic EHPVO
177–179]. Frequently the foetal outcome is poor. Mortality, mainly
ue to bleeding and preeclampsia, occurs in 4–10% of cases.
pper endoscopy, before pregnancy and at the end of the second
rimester, even in women without varices before, is recommended
45] (Class I, Level C). Non-selective beta-blockers, albeit with
he sporadic risk of intrauterine growth retardation and foetal Disease 48 (2016) 120–137
bradycardia, or endoscopic variceal band ligation, are recom-
mended for large-sized varices [180,181]. If anticoagulation is
required (persistent thrombotic risk), LMWH  at therapeutic dose
must replace VKA and anti-platelet agents, before conception or as
soon as possible. Because of placental heparinase and the increased
glomerular ﬁltration rate and distribution volume in pregnancy,
anti-Xa activity should be checked once a month [182]. Antico-
agulation, with LMWH  or VKA, can be restarted 12 hours after
delivery (or 24 hours after caesarean section). Breast-feeding is
contraindicated in women  taking LMWH,  but not in women  tak-
ing VKA, which are excreted inactive in maternal milk (Class I,
Level C).
Miscarriage, prematurity, small for gestational age infants and
perinatal death are increased in women with chronic EHPVO [183].
Caesarean section is hazardous for possible pelvic varices, and
should be restricted to obstetric indications (Class I, Level C).
In a recent multicentre study [184] evaluating the maternal and
foetal outcome of 45 pregnancies in 24 women with chronic EHPVO,
miscarriage occurred in 20% and preterm birth in 38% of preg-
nancies. Variceal bleeding occurred in three patients, all without
prophylaxis. HELLP syndrome occurred in two. Genital or pari-
etal bleeding occurred postpartum in four patients, of which only
one was on anticoagulants. Thrombotic events occurred in two
patients. There were no maternal deaths. Overall, a favourable out-
come (live birth at 32 or more weeks of gestation, with a healthy
infant and no serious obstetrical complication) occurred in 64% of
pregnancies.
AISF expert panel recommendations:
• Pregnancy is not absolutely contraindicated in women with
stable chronic EHPVO. However, maternal morbidity is
increased. Anticoagulation, with LMWH  is indicated in per-
manent pro-thrombotic disorders. Prophylaxis of variceal
bleeding is mandatory (Class I, Level C).
• Breast-feeding is contraindicated in women  taking LMWH,  but
not in women taking VKA (Class I, Level C).
4.8.3. Idiopathic non-cirrhotic portal hypertension
Portal hypertension with patent portal and hepatic veins,
absence of cirrhosis, and exclusion of other common causes of
liver disease deﬁnes idiopathic non-cirrhotic portal hypertension
(INCPH). This term has been proposed instead of hepatopor-
tal sclerosis, non-cirrhotic portal ﬁbrosis or idiopathic portal
hypertension, which indicate, apparently distinct although over-
lapping features of a unique vascular disorder. INCPH accounts
for about 25% of patients with portal hypertension in develop-
ing countries. Thrombophilia may  have a role, at least in the
West [185].
Main features of INCPH include splenomegaly, portal hyper-
tension with repeated variceal bleeds. Liver function is usually
preserved. Rare complications include jaundice, ascites and
encephalopathy.
Complications during pregnancy include variceal bleeding,
anaemia, and thrombocytopenia due to hypersplenism. A recent
study in pregnant women with INCPH suggests normal fertil-
ity, non-increased incidences of miscarriages and stillbirths, but
a higher risk of small for gestational age infants [186]. As in EHPVO,
there is no role of elective caesarean section, apart from obstetric
indications (Class I, Level C).
AISF expert panel recommendations:• Pregnancy is not absolutely contraindicated in women with
INCPH. However, maternal morbidity is increased. Antico-
agulation is currently not indicated. Prophylaxis of variceal
bleeding is mandatory (Class I, Level C).
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Table 5
Safety pharmacotherapy and procedures for portal hypertension during pregnancy.
Drug FDA class Used and safety
Beta-blockers
1st trimester C Close foetal monitoring needed to avoid
foetal bradycardia and intrauterine growth
retardation.2nd/3rd trimester D
Octreotide B Use is controversial, limited by splanchnic
vasoconstriction precipitating placental
ischaemia and abruption.
Vasopressin X Absolutely contraindicated due to uterine
ischaemia.
Band ligation Safe and effective from the 2nd trimester
of pregnancy.
TIPS Use is controversial due to exposure of the
foetus to radiation.Special Article / Digestive and
In women with INCPH breast-feeding is not contraindi-
cated.
.8.4. Hereditary haemorrhagic telangiectasia
Hereditary haemorrhagic telangiectasia (HHT) is an inherited
utosomal dominant disease featuring abnormal blood vessels and
rteriovenous ﬁstulas in multiple organs.
HHT worsens in pregnancy, mainly in pulmonary or cerebral
ocalizations, and improves postpartum.
Among 47 women and 161 pregnancies, worsening of intrapul-
onary shunts occurred in six, with fatal pulmonary haemorrhage
n two, and stroke in 3 [187].
Hepatic vascular malformations, often formerly unrecognized,
ay  become symptomatic in pregnancy [188]. Anecdotal cases of
ongestive heart failure from hepatic arteriovenous ﬁstulas with
pontaneous improvement after delivery [189], as well as cases of
iliary necrosis are reported [190,191].
ISF expert panel recommendations:
Maternal morbidity and mortality are increased in HHT.
Women  must be counselled on the risks associated with preg-
nancy (Class I, Level C).
In women with HHT breast-feeding is not contraindicated.
.9. Cirrhosis and portal hypertension
Pregnancy is uncommon in women with liver cirrhosis, because
hey tend to be past childbearing age or infertile due to the con-
ition. Cirrhosis leads to anovulation and amenorrhea because
f many factors including disturbed of oestrogen and endocrine
etabolism. When pregnancy is successful in a cirrhotic woman,
pontaneous abortion rate, risk of prematurity, and perinatal death
ate are all increased [13]. Unfortunately, the outcomes and the
ptimal management of pregnancy with cirrhosis and portal hyper-
ension in the modern era of obstetrics is still undeﬁned [45].
urther, a rate of maternal mortality up to 5–10% has been described
n this group of patients. Maternal prognosis depends on the degree
f hepatic dysfunction during pregnancy rather than its cause
13,142].
Recently, Westbrook et al. demonstrated that Model for
nd-stage liver disease (MELD) score is useful to predict liver
ecompensation in pregnant women with cirrhosis. Indeed, no
atient with MELD score ≤6 developed any signiﬁcant liver com-
lications [192].
Portal hypertension worsens during pregnancy because of
ncreased blood volume and ﬂow, and further increased vascular
esistance due to external compression of the inferior vena cava
y the gravid uterus. Indeed, up to 25% of patients with varices
ave a bleeding episode during pregnancy. The greatest risk is seen
n the second trimester (when portal pressures peak), and during
elivery, because of the repeated use of the Valsalva manoeuvre
uring expulsion. However, there are no clear recommendation
egarding mode of delivery [142,193], even if caesarean section is
ecommended in patients with large oesophageal or gastric varices;
isk of vaginal delivery in patients with small varices is unknown
193,194].
Regarding the treatment of variceal bleeding during pregnancy,
ll cirrhotic patients should undergo variceal screening by upper
ndoscopy. Banding before pregnancy is appropriate for high-risk
arices, although ofﬁcial guidelines are lacking. TIPS can be con-
idered in extreme cases of variceal bleeding, although there is
isk of radiation exposure to the foetus. Propranolol has also been
sed safely in pregnancy. Side effects include foetal growth retar-
ation, neonatal bradycardia and hypoglycaemia. Propranolol does
ot appear to be teratogenic, but maternal and foetal propranololTIPS, transjugular intrahepatic porto-systemic shunt.
toxicity may  occur. Terlipressin has not been studied in preg-
nancy. Many concerns exist about decreased placental perfusion
and increased risk of placental abruption (Table 5) [142,194].
Pregnant patients with cirrhosis have an increased risk of splenic
artery aneurysm rupture, which occurs in 2.6% of patients. More
than 20% of all splenic artery aneurysm ruptures occurs during the
third trimester, and may  be related to increased splenic ﬂow from
both pregnancy and portal hypertension [195]. Therefore, an ultra-
sound examination of the splenic artery should be performed in
early pregnancy, to exclude pre-existing splenic artery aneurysm.
Furthermore, dietary sodium restriction to reduce ﬂuid retention
and portal pressure is recommended [142].
Since data on safety of breast-feeding in cirrhosis are scarce,
all medications used during breast-feeding should be checked for
infant exposure risk.
The outcome of pregnancy in patients with non-cirrhotic portal
hypertension (NCPH) is more favourable. Recent studies in women
with NCPH show near normal fertility with comparable incidences
of spontaneous abortions and stillbirths. No increase in the inci-
dence of hematemesis during pregnancy has been observed. In this
setting, a higher risk of SGA babies has been reported [196].
AISF expert panel recommendations:
• Pregnancy is uncommon in women with liver cirrhosis. When
it occurs, spontaneous abortion rates (15–20%), risk of pre-
maturity (26–64%) and perinatal death rate are increased
compared to general population. Maternal prognosis of
patients with portal hypertension depends on the degree of
hepatic dysfunction assessed by MELD score and maternal
mortality is 5–10% (Class III, Level A).
• Oesophageal variceal bleeding rate is high in pregnant cir-
rhotic women with varices (up to 25%). A screening endoscopy
is recommended before or early in the second trimester of
gestation (Class III, Level A). Pregnant patients with medium-
to-large varices must be treated with non-selective -blockers
or band ligation (Class III, Level B).
• Caesarean section is recommended in pregnant women  with
cirrhosis with large oesophageal or gastric varices (Class III,
Level A); risk of vaginal delivery in patients with small varices
is unknown (Class III, Level C).
• Since data on safety of breast-feeding in cirrhosis are scarce,
all medications used during breast-feeding should be checked
for infant exposure risk.Conﬂict of interest
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